Representative experience

Novartis on its acquisition of IFM Tre for up to US$1.6bn and its option to acquire IFM Due for up to US$840m.

Celgene Corporation, on its US$9bn acquisition of Juno Therapeutics, a clinical-stage cell immunotherapy company.

Novartis, on its US$8.7bn acquisition of AveXis Inc., a clinical-stage gene therapy biotech company.

Shire on the ex-U.S. aspects of its US$2.4bn oncology business sale to Servier S.A.S.

Celgene Corporation, on its acquisition of Impact Biomedicines for up to US$7bn, a clinical stage company developing fedratinib for myelofibrosis.

Chase Pharmaceuticals on its sale to Allergan for up to US$1bn.

Allergan on its US$40.5bn generics divestiture to Teva Pharmaceuticals.

Alcon Laboratories on its acquisitions of Encore Vision, RxSight, and Transcend Medical.

Novartis in the acquisition from GSK of rights to Arzerra® (ofatumumab) for auto-immune indications for more than US$1bn.

Kite, a Gilead company, in an up to US$3bn deal to access Sangamo Therapeutics' zinc finger nuclease technology.

Celgene on strategic collaborations and equity investments, including with Kyn Therapeutics, Ex Scientia, Obsidian Therapeutics, Jounce Therapeutics, and Skyhawk Therapeutics.

Gilead Sciences on its US$150m collaboration with Agenus to develop and commercialize up to five novel immuno-oncology therapies.

Novartis on its collaboration with Cellular Biomedicine Group to support the introduction of the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China.

Gilead Sciences on its strategic partnership with Goldfinch Bio, to develop and commercialize innovative therapeutics for kidney diseases.

Bausch Health (formerly Valeant) on the sale of Dendreon Pharmaceuticals to the Sanpower Group Co., Ltd., one of the largest privately owned conglomerates in China.

Gilead Sciences on its strategic collaboration with Tango Therapeutics, to develop and commercialize innovative targeted immuno-oncology treatments for cancer.

Novartis on strategic collaborations with Surface Therapeutics, Xencor, and Homology Medicines.

Novartis in connection with its landmark portfolio transformation transactions with GSK and Eli Lilly worth more than US$23bn.

Buyers and sellers of FDA priority review vouchers.